Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

New AI-led science initiative will help protect communities hit by climate change in East Africa

Innovation Research

The United Nations World Food Programme (WFP), Oxford University Physics Department, IGAD Climate Prediction and Applications Centre (ICPAC), and various national forecasting and meteorology agencies across east Africa are joining forces to pioneer a transformative initiative that is revolutionising extreme weather forecasting and early warning systems in the region.

KEMRI Wellcome Trust Research Programme (KWTRP) Annual Policy Engagement Forum


The KEMRI Wellcome Trust Research Programme (KWTRP) hosted its annual policy engagement forum in Nairobi. This year’s forum provided a valuable platform for deliberation between policy stakeholders and researchers, focusing on their research needs and policy priorities.

Department's Centre for Research Equity launches historic partnership to advance health equity in Northern Ireland


Department's Centre for Research Equity partners with Northern Ireland to advance health equity. This groundbreaking collaboration aims to improve health outcomes, reduce disparities, and ensure research benefits all communities through inclusive, community-driven approaches.

First UK trial of Deep Brain Stimulation for children with epilepsy begins


A teenager who is the first patient to take part in a UK clinical trial to use deep brain stimulation to treat epilepsy has seen his daytime seizures reduce by 80%.

Cholesterol-lowering drug slows progression of eye disease in people with diabetes


The LENS trial has demonstrated that fenofibrate, a drug usually used to lower cholesterol, reduces the risk of progression of diabetic retinopathy by 27%. The results were announced today at the American Diabetes Association Scientific Sessions and published in NEJM Evidence.

Cross-species immune responses could lead to innovative treatments


A new study published by Oxford researchers as part of an international collaboration in the Journal of Biological Chemistry has found that an important section of our immune system, that involves the molecule MR1 and MAIT cells, is evolutionarily conserved in multiple species.

Sepsis patients could get the right treatment faster based on their genes


Sepsis patients could be treated based on their immune system’s response to infection, not their symptoms. New research uncovers how different people respond to sepsis based on their genetic makeup, which could help identify who would benefit from certain treatments and lead to the development of targeted therapies.

Novel data method sheds light on hidden patterns of kidney inflammation


Globally kidney disease is forecast to be the 5th leading cause of death by 2040, and in the UK more than 3 million people are living with the most severe stages of chronic kidney disease. Chronic kidney disease is often due to autoimmune damage to the filtration units of the kidney, known as the glomeruli, which can occur in lupus, a disease which disproportionally affects women and people of non-white ethnicities, groups often underrepresented in research. Treatment options are limited, can have life threatening side-effects and often don’t slow the disease, which can then progress to end stage, requiring dialysis or a kidney transplant.

OUCRU Hosts “Agent-based Modelling (ABM) with GAMA” Course: Potential Application in Health Sciences


In June 2024, OUCRU organised a training course "Agent-based Modelling (ABM) with GAMA" in Ho Chi Minh City. Participants from multiple countries explored the practical application of ABM in health science through theoretical lectures, practical sections, and collaborative group projects.

Existing interventions are effective in reducing antimicrobial resistance


In a new study published in The Lancet, a team of international researchers has highlighted the urgent need for action to address the growing threat of antibiotic resistance.

Shipment of R21 malaria vaccine to Central African Republic marks latest milestone for child survival

Public engagement

Last month, UNICEF delivered over 43,200 doses of the R21/Matrix-M malaria vaccine developed through collaboration between Oxford University’s Jenner Institute and Serum Institute of India leveraging by Novavax’s saponin-based adjuvant technology, by air to Bangui, Central African Republic, with further shipment of about 163,800 doses to follow, which is allocated for children in the CAR currently.

Communication, Narratives and Antimicrobial Resistance

Events Innovation

The World Health Organisation has declared Antimicrobial Resistance (AMR) as one of the ‘top global and public health development threats.’ The Communication, Narratives and Antimicrobial Resistance conference took place on the 16th of May at Merton College, Oxford, as part of the TORCH Medical Humanities programme in an effort to approach the problem from a Humanities perspective. The focus of the day was the power of narrative and communication in discussions around antimicrobial resistance. This blog reviews the discussions of the day. Written by Alberto Giubilini, Sally Frampton, Tess Johnson and Will Matlock

New small molecule found to suppress the evolution of antibiotic resistance in bacteria

Innovation Research

Researchers from the Ineos Oxford Institute for antimicrobial research (IOI) and the Department of Pharmacology at Oxford University, have developed a new small molecule that can suppress the evolution of antibiotic resistance in bacteria and make resistant bacteria more susceptible to antibiotics.

Forecasting how best to control and eliminate Neglected Tropical Diseases

Innovation Partnerships Research

Neglected tropical diseases (NTDs) are a major cause of death, disability, and economic hardship worldwide, particularly in low- and middle-income countries. While many of these diseases are targeted for control, elimination, or eradication by 2030, achieving those targets will be challenging due to disruptions to programmes related to the COVID-19 pandemic and differences in disease transmission across regions, which requires tailoring interventions to local settings.

Interview with Diagnostics in Tropical and Infectious Diseases(DiTi) award recipient Dr Christopher Chew

Awards and Appointments General Partnerships Staff and Student stories

Global Health research at the University of Oxford and its partners is broad reaching, bringing significant impact across all academic disciplines of medicine, the physical and life sciences, social sciences and humanities. The Diagnostics in Tropical and Infectious Disease (DiTi) award, run by the Translational Research Office, aims to strengthen the long-term partnership between Oxford University and Mahidol University by establishing partnerships and supporting collaborative projects to develop diagnostic devices for tropical and infectious diseases, with the goal of driving more translational research initiatives in global health. Read this interview from award winner Dr Chris Chew.

Sixty Seconds with Professor Alan Bernstein

General Staff and Student stories

Professor Alan Bernstein is Director of Global Health. The Oxford Global Health initiative brings together researchers from diverse disciplines and showcases the ongoing range of impactful global health research at Oxford. In this Sixty Seconds interview, we hear from Alan about his career to date, his vision for Oxford Global Health, and the lessons he has learnt throughout his career.

Novel inhaled TB vaccine

General Research

The Jenner Institute is conducting a new study, using BCG, the current licensed vaccine against tuberculosis. In this study, they will give BCG a second time to people who have already had BCG once before, and will compare whether giving it by inhalation is better at protecting people against tuberculosis than giving it into the skin

First-in-human vaccine trial for deadly Nipah virus launched

Clinical Trials General Research

First clinical trial participants received doses of the ChAdOx1 NipahB vaccine over the last week at University of Oxford. UK trial is first step to developing a vaccine against Nipah virus – a devastating disease mostly found in South-East Asia – that can be fatal in up to 75% of cases. The milestone clinical trial comes as the global health community marks the 25th anniversary of the first Nipah virus outbreaks. There are still no approved vaccines or treatments for the disease.

Sir Stewart Cole joins the Ineos Oxford Institute for antimicrobial research as Executive Chair

Awards and Appointments General

Sir Stewart Cole, KCMG, FRS has joined the Ineos Oxford Institute for antimicrobial research (IOI) as Executive Chair. The IOI is a world-leading centre of research, training, and education in the field of antimicrobial resistance (AMR) based at the University of Oxford. It was established thanks to an unprecedented £100 million gift from INEOS, one of the world’s largest chemical companies.

Load More